Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on August 14, 2025
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
August 14, 2025
– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind …
Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results
GlobeNewswire
·
August 14, 2025
Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney …
CooperCompanies to Participate in the Wells Fargo Healthcare Conference
GlobeNewswire
·
August 14, 2025
SAN RAMON, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025. Al White, President …
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
GlobeNewswire
·
August 14, 2025
Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a …
Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025
GlobeNewswire
·
August 14, 2025
ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial …
BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for …
Shuttle Pharma Provides Second Quarter 2025 Corporate Update
GlobeNewswire
·
August 14, 2025
GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …
CMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South Sudan
GlobeNewswire
·
August 14, 2025
Juba, South Sudan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is launching an emergency response in South Sudan as compounding crises threaten thousands of lives in Upper Nile region and Central Equatoria State. The devastating …
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
August 14, 2025
Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right (CVR), plus a 2.5% royalty on future net sales of …
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt …
GT Biopharma Reports Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and initiated dosing of the fifth patient in the study; …
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
August 14, 2025
– Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of 2026 – Phase 1/ …
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
August 14, 2025
Presented positive translational data from SYNGAP1-related disorders program showcasing efficacy in a humanized SYNGAP mouse model and increased protein in non-human primates at the 28th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting …
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025
GlobeNewswire
·
August 14, 2025
PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …
Venus Concept Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025. Summary of …
Nasus Pharma Announces Closing of Initial Public Offering
GlobeNewswire
·
August 14, 2025
TEL AVIV, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions …
Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
August 14, 2025
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption submission to FDA of novel CBGM technology in Q4 …
Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption
GlobeNewswire
·
August 14, 2025
EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“ …
TOMI Environmental Solutions, Inc. Reports Q2 2025 Financial Results and Outlines Growth Initiatives
GlobeNewswire
·
August 14, 2025
FREDERICK, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced …
Profound Medical Announces Second Quarter 2025 Financial Results
GlobeNewswire
·
August 14, 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation …